Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes | Cardiovascular Diabetology | Full Text
Efficacy and safety of once‐weekly exenatide after switching from twice‐daily exenatide in patients with type 2 diabetes - Watanabe - 2020 - Journal of Diabetes Investigation - Wiley Online Library
ADA: Efficacy and Safety of Lixisenatide Once-Daily vs. Exenatide Twice-Daily in Type 2 DM Inadequately Controlled on Metformin (GetGoal-X)
GLP-1 Receptor Agonists in Type 2 Diabetes and Beyond - New Insights 2015. - Abstract - Europe PMC
Efficacy and safety of dulaglutide versus placebo and exenatide in type 2 diabetes (AWARD-1) - Virtual Meeting | EASD
Simulated progression of HbA1c in exenatide BID þ OAD (treatment arm)... | Download Scientific Diagram
![PDF] Exenatide twice daily versus insulin glargine for the treatment of type 2 diabetes in Poland - subgroup data from a randomised multinational trial GWAA. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/f043112b89c611063f7e12c342d0e40ccc072578/5-TableIII-1.png "PDF] Exenatide twice daily versus insulin glargine for the treatment of type 2 diabetes in Poland - subgroup data from a randomised multinational trial GWAA. | Semantic Scholar")
PDF] Exenatide twice daily versus insulin glargine for the treatment of type 2 diabetes in Poland - subgroup data from a randomised multinational trial GWAA. | Semantic Scholar
Estimated average daily usage and cost of exenatide BiD and liraglutide... | Download Table
Therapy escalation options for patients failing therapy with exenatide BID + metformin or glimepiride + metformin: results from the EUREXA clinical study - Virtual Meeting | EASD
Compare Diabetes Drugs
Safety and tolerability of exenatide once weekly in patients with type | DMSO
![PDF] Exenatide twice daily versus insulin glargine for the treatment of type 2 diabetes in Poland - subgroup data from a randomised multinational trial GWAA. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/f043112b89c611063f7e12c342d0e40ccc072578/6-TableIV-1.png "PDF] Exenatide twice daily versus insulin glargine for the treatment of type 2 diabetes in Poland - subgroup data from a randomised multinational trial GWAA. | Semantic Scholar")
PDF] Exenatide twice daily versus insulin glargine for the treatment of type 2 diabetes in Poland - subgroup data from a randomised multinational trial GWAA. | Semantic Scholar
Comparison between twice-daily (BID) exenatide (10 mg) and once-daily... | Download Scientific Diagram
Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes | Cardiovascular Diabetology | Full Text
MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes? in: European Journal of Endocrinology Volume 181 Issue 6 (2019)
Public reimbursed prices of exenatide BiD and liraglutide in germany,... | Download Table
Abstract 13242: Risk of Cardiovascular Events in Patients with Type 2 Diabetes Treated With Exenatide BID or Other Glucose-Lowering Therapies: A Retrospective Analysis of the LifeLinkTM Database | Circulation
Exenatide Twice Daily Plus Glargine Versus Aspart 70/30 Twice Daily in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Premixed Human Insulin and Metformin - Endocrine Practice
![PDF] Exenatide twice daily versus insulin glargine for the treatment of type 2 diabetes in Poland - subgroup data from a randomised multinational trial GWAA. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/f043112b89c611063f7e12c342d0e40ccc072578/4-Figure1-1.png "PDF] Exenatide twice daily versus insulin glargine for the treatment of type 2 diabetes in Poland - subgroup data from a randomised multinational trial GWAA. | Semantic Scholar")
PDF] Exenatide twice daily versus insulin glargine for the treatment of type 2 diabetes in Poland - subgroup data from a randomised multinational trial GWAA. | Semantic Scholar
Exenatide twice-daily does not affect renal function or albuminuria compared to titrated insulin glargine in patients with type 2 diabetes mellitus: A post-hoc analysis of a 52-week randomised trial - Diabetes Research
Study design of DURATION-1. BID, twice daily; GLT, glucose-lowering... | Download Scientific Diagram
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. - Abstract - Europe PMC
